2v1y: Difference between revisions

No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Many human cancers involve up-regulation of the phosphoinositide 3-kinase, PI3Kalpha, with oncogenic mutations identified in both the p110alpha, catalytic and the p85alpha regulatory subunits. We used crystallographic, and biochemical approaches to gain insight into activating mutations in, two noncatalytic p110alpha domains-the adaptor-binding and the helical, domains. A structure of the adaptor-binding domain of p110alpha in a, complex with the p85alpha inter-Src homology 2 (inter-SH2) domain shows, that oncogenic mutations in the adaptor-binding domain are not at the, inter-SH2 interface but in a polar surface patch that is a plausible, docking site for other domains in the holo p110/p85 complex. We also, examined helical domain mutations and found that the Glu545 to Lys545, (E545K) oncogenic mutant disrupts an inhibitory charge-charge interaction, with the p85 N-terminal SH2 domain. These studies extend our understanding, of the architecture of PI3Ks and provide insight into how two classes of, mutations that cause a gain in function can lead to cancer.
Many human cancers involve up-regulation of the phosphoinositide 3-kinase PI3Kalpha, with oncogenic mutations identified in both the p110alpha catalytic and the p85alpha regulatory subunits. We used crystallographic and biochemical approaches to gain insight into activating mutations in two noncatalytic p110alpha domains-the adaptor-binding and the helical domains. A structure of the adaptor-binding domain of p110alpha in a complex with the p85alpha inter-Src homology 2 (inter-SH2) domain shows that oncogenic mutations in the adaptor-binding domain are not at the inter-SH2 interface but in a polar surface patch that is a plausible docking site for other domains in the holo p110/p85 complex. We also examined helical domain mutations and found that the Glu545 to Lys545 (E545K) oncogenic mutant disrupts an inhibitory charge-charge interaction with the p85 N-terminal SH2 domain. These studies extend our understanding of the architecture of PI3Ks and provide insight into how two classes of mutations that cause a gain in function can lead to cancer.


==About this Structure==
==About this Structure==
Line 15: Line 15:
[[Category: Phosphatidylinositol-4,5-bisphosphate 3-kinase]]
[[Category: Phosphatidylinositol-4,5-bisphosphate 3-kinase]]
[[Category: Protein complex]]
[[Category: Protein complex]]
[[Category: Backer, J.M.]]
[[Category: Backer, J M.]]
[[Category: Hon, W.C.]]
[[Category: Hon, W C.]]
[[Category: Inbar, Y.]]
[[Category: Inbar, Y.]]
[[Category: Miled, N.]]
[[Category: Miled, N.]]
[[Category: Perisic, O.]]
[[Category: Perisic, O.]]
[[Category: Schneidman-Duhovny, D.]]
[[Category: Schneidman-Duhovny, D.]]
[[Category: Williams, R.L.]]
[[Category: Williams, R L.]]
[[Category: Wolfson, H.J.]]
[[Category: Wolfson, H J.]]
[[Category: Yan, Y.]]
[[Category: Yan, Y.]]
[[Category: Zvelebil, M.]]
[[Category: Zvelebil, M.]]
Line 43: Line 43:
[[Category: ubl conjugation]]
[[Category: ubl conjugation]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 14:27:50 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:52:36 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA